Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Tuesday

Nurix Therapeutics (NASDAQ:NRIX) is projected to release its Q4 2025 results before the market opens on Tuesday, January 27th. Analysts expect Nurix Therapeutics to post earnings of ($0.86) per share and revenue of $13.4140 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 12:00 AM ET.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $18.56 on Friday. Nurix Therapeutics has a one year low of $8.18 and a one year high of $22.50. The stock has a fifty day moving average of $18.13 and a 200 day moving average of $13.18. The stock has a market cap of $1.43 billion, a PE ratio of -6.25 and a beta of 1.93.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 6,284 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. The trade was a 14.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 4,087 shares of the company’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $12.80, for a total transaction of $52,313.60. Following the transaction, the insider owned 76,751 shares of the company’s stock, valued at approximately $982,412.80. This represents a 5.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 13,501 shares of company stock worth $171,305. 7.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wexford Capital LP bought a new stake in shares of Nurix Therapeutics in the third quarter worth about $41,000. Tower Research Capital LLC TRC raised its holdings in shares of Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after acquiring an additional 3,475 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of Nurix Therapeutics during the 3rd quarter valued at approximately $100,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Nurix Therapeutics in the third quarter valued at $109,000. Finally, Velan Capital Investment Management LP grew its holdings in shares of Nurix Therapeutics by 60.0% in the third quarter. Velan Capital Investment Management LP now owns 16,000 shares of the company’s stock valued at $148,000 after purchasing an additional 6,000 shares in the last quarter.

Wall Street Analyst Weigh In

NRIX has been the subject of a number of recent research reports. Morgan Stanley set a $36.00 price objective on shares of Nurix Therapeutics and gave the company an “overweight” rating in a research report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday. Royal Bank Of Canada restated an “outperform” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, October 22nd. Oppenheimer lowered their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Friday, October 10th. Finally, Stifel Nicolaus set a $33.00 target price on shares of Nurix Therapeutics in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.13.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.